Latest Close
$61.03
News
ARWR
Arrowhead Pharmaceuticals, Inc. News
This news view pulls recent coverage and headlines tied to ARWR.
1y Change
$48.97 (+406.05%)
Market Cap
$8.55B
Sector
Healthcare
Industry
Biotechnology
Recommendation
buy
Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential
Simply Wall St. • Mar 29, 2026
Read articleArrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Business Wire • Mar 28, 2026
Read articleSRPT Stock Surges on Promising Early Results From siRNA Programs
Zacks • Mar 26, 2026
Read articleJohnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets
Barrons.com • Mar 25, 2026
Read articleSarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
24/7 Wall St. • Mar 25, 2026
Read articleSarepta sees early success with RNAi drugs from Arrowhead
BioPharma Dive • Mar 25, 2026
Read article